Literature DB >> 22337280

Prophylaxis in haemophilia should be life-long.

Mike Makris1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22337280      PMCID： PMC3320774          DOI： 10.2450/2012.0147-11

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  20 in total

1.  Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.

Authors:  G C White; F Rosendaal; L M Aledort; J M Lusher; C Rothschild; J Ingerslev
Journal:  Thromb Haemost       Date:  2001-03       Impact factor: 5.249

2.  Prophylactic treatment for prevention of joint disease in hemophilia--cost versus benefit.

Authors:  Goris Roosendaal; Floris Lafeber
Journal:  N Engl J Med       Date:  2007-08-09       Impact factor: 91.245

Review 3.  When to start and when to stop primary prophylaxis in patients with severe haemophilia.

Authors:  J Astermark
Journal:  Haemophilia       Date:  2003-05       Impact factor: 4.287

4.  Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands.

Authors:  K van Dijk; K Fischer; J G van der Bom; E Scheibel; J Ingerslev; H M van den Berg
Journal:  Br J Haematol       Date:  2005-07       Impact factor: 6.998

Review 5.  Thrombin generation testing in routine clinical practice: are we there yet?

Authors:  J J van Veen; A Gatt; M Makris
Journal:  Br J Haematol       Date:  2008-06-28       Impact factor: 6.998

6.  Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices.

Authors:  C E Walsh; L A Valentino
Journal:  Haemophilia       Date:  2009-06-01       Impact factor: 4.287

7.  Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology.

Authors:  D Keeling; C Tait; M Makris
Journal:  Haemophilia       Date:  2008-04-04       Impact factor: 4.287

8.  Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data.

Authors:  M Richards; C Altisent; A Batorova; H Chambost; G Dolan; P de Moerloose; M Fraga; C Hermans; A Karafoulidou; R Klamroth; R Lassila; C Rothschild
Journal:  Haemophilia       Date:  2007-09       Impact factor: 4.287

9.  Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study.

Authors:  P Collins; A Faradji; M Morfini; M M Enriquez; L Schwartz
Journal:  J Thromb Haemost       Date:  2009-10-11       Impact factor: 5.824

10.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.

Authors:  Marilyn J Manco-Johnson; Thomas C Abshire; Amy D Shapiro; Brenda Riske; Michele R Hacker; Ray Kilcoyne; J David Ingram; Michael L Manco-Johnson; Sharon Funk; Linda Jacobson; Leonard A Valentino; W Keith Hoots; George R Buchanan; Donna DiMichele; Michael Recht; Deborah Brown; Cindy Leissinger; Shirley Bleak; Alan Cohen; Prasad Mathew; Alison Matsunaga; Desiree Medeiros; Diane Nugent; Gregory A Thomas; Alexis A Thompson; Kevin McRedmond; J Michael Soucie; Harlan Austin; Bruce L Evatt
Journal:  N Engl J Med       Date:  2007-08-09       Impact factor: 91.245
View more
  26 in total

1.  Prophylaxis for adults with haemophilia: towards a personalised approach?

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2012-02-13       Impact factor: 3.443

Review 2.  Present and future challenges in the treatment of haemophilia: the patient's perspective.

Authors:  Romano Arcieri; Angelo C Molinari; Stefania Farace; Giuseppe Mazza; Alberto Garnero; Gabriele Calizzani; Paola Giordano; Emily Oliovecchio; Lorenzo Mantovani; Lamberto Manzoli; Paul Giangrande
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 3.  The demand for factor VIII and for factor IX and the toll fractionation product surplus management.

Authors:  Gabriele Calizzani; Samantha Profili; Fabio Candura; Monica Lanzoni; Stefania Vaglio; Livia Cannata; Giancarlo M Liumbruno; Massimo Franchini; Pier Mannuccio Mannucci; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

4.  The increased demand for plasma-derived factor VIII in Italy.

Authors:  Romano Arcieri; Gabriele Calizzani; Fabio Candura; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2016-07-28       Impact factor: 3.443

5.  Intermediate Dose Prophylaxis in Adults with Haemophilia: A Clinical Audit from a Resource Limited Setting.

Authors:  Remya Sudevan; Aswathy Ashok Beenakumari; Rema Ganapathy; Manoj Unni; Geeta Vidyadharan; Neeraj Sidharthan
Journal:  Indian J Hematol Blood Transfus       Date:  2019-09-18       Impact factor: 0.900

Review 6.  Efmoroctocog Alfa: A Review in Haemophilia A.

Authors:  James E Frampton
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

Review 7.  Low Dose Prophylaxis in Hemophilia Care.

Authors:  Neeraj Sidharthan; Remya Sudevan
Journal:  Indian J Hematol Blood Transfus       Date:  2019-06-15       Impact factor: 0.900

Review 8.  Coagulation Factor IX (Recombinant), Albumin Fusion Protein (Albutrepenonacog Alfa; Idelvion®): A Review of Its Use in Haemophilia B.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

9.  Effect of comorbidities on the association between age and hospital mortality after fall-related hip fracture in elderly patients.

Authors:  A Padrón-Monedero; T López-Cuadrado; I Galán; E V Martínez-Sánchez; P Martin; R Fernández-Cuenca
Journal:  Osteoporos Int       Date:  2017-02-03       Impact factor: 4.507

10.  Gene-based FVIIa prophylaxis modulates the spontaneous bleeding phenotype of hemophilia A rats.

Authors:  Shannon M Zintner; Juliana C Small; Giulia Pavani; Lynn Dankner; Oscar A Marcos-Contreras; Phyllis A Gimotty; Mads Kjelgaard-Hansen; Bo Wiinberg; Paris Margaritis
Journal:  Blood Adv       Date:  2019-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.